Amgen Inc. or PTC Therapeutics, Inc.: Who Leads in Yearly Revenue?

Amgen Inc. vs. PTC Therapeutics, Inc.: A Revenue Showdown

In the competitive landscape of biotechnology, Amgen Inc. and PTC Therapeutics, Inc. have carved distinct paths. Over the past decade, Amgen has consistently outperformed PTC Therapeutics in terms of revenue. From 2014 to 2023, Amgen's revenue surged by approximately 40%, reaching a peak in 2023. In contrast, PTC Therapeutics, while showing impressive growth, increased its revenue by over 3,900% during the same period, albeit from a much smaller base.

Amgen's dominance is evident, with its 2023 revenue being nearly 30 times that of PTC Therapeutics. However, PTC's rapid growth trajectory highlights its potential in the biotech sector. This revenue analysis not only underscores Amgen's established market presence but also PTC's emerging influence, making it a company to watch in the coming years.